Drugs that contain Carvedilol Phosphate
1. Coreg Cr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7268156 | WOODWARD | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
Jun, 2023
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE40000 | WOODWARD | Method of treatment for decreasing mortality resulting from congestive heart failure |
Jun, 2015
(8 years ago) | |
| US6022562 | WOODWARD | Medicinal and/or nutritional microcapsules for oral administration |
Oct, 2015
(8 years ago) | |
|
USRE40000 (Pediatric) | WOODWARD | Method of treatment for decreasing mortality resulting from congestive heart failure |
Dec, 2015
(8 years ago) | |
|
US6022562 (Pediatric) | WOODWARD | Medicinal and/or nutritional microcapsules for oral administration |
Apr, 2016
(8 years ago) | |
|
US7268156 (Pediatric) | WOODWARD | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
Dec, 2023
(3 months ago) | |
| US8101209 | WOODWARD | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
Sep, 2025
(1 year, 4 months from now) | |
|
US8101209 (Pediatric) | WOODWARD | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
Mar, 2026
(1 year, 10 months from now) | |
Market Authorisation Date: 20 October, 2006
Treatment: Decreasing mortality caused by congestive heart failure; Treatment of hypertension
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of COREG CR before it's drug patent expiration?
More Information on Dosage
COREG CR family patents
